Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 8Head & Neck 4Thoracic 3Breast 3Sarcoma 1Gynecologic 1

Conditions

Small Cell Lung Carcinoma 3Recurrence 1

Interventions

Carboplatin 1152Cisplatin 876Pemetrexed 834pembrolizumab 608Paclitaxel 598Docetaxel 535Gemcitabine 424Radiotherapy 377Erlotinib Hydrochloride 367Nivolumab 322Bevacizumab 322Etoposide 295durvalumab 254Drug Therapy 233osimertinib 218atezolizumab 208Radiosurgery 190Gefitinib 177Vinorelbine 145130-nm albumin-bound paclitaxel 124Magnetic Resonance Spectroscopy 121Ipilimumab 118Cetuximab 113anlotinib 104tislelizumab 103Topotecan 101Cyclophosphamide 101Taxes 99Irinotecan 95Albumin-Bound Paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × lobaplatin × Thoracic × Clear all
NCT03613597 2020-02-05

Etoposide Plus Lobaplatin Versus Etoposide Plus Cisplatin for Patients With Limited Small-cell Lung Cancer

Guizhou Medical University

Phase 2 Unknown
118 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT03613753 2020-02-05

Irinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung Cancer

Guizhou Medical University

Phase 2 Unknown
72 enrolled
Thoracic

Recurrence, Small Cell Lung Carcinoma

NCT03700359 2019-11-29

A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC

The First Affiliated Hospital of Guangzhou Medical University

Phase 2 Unknown
60 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡